Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity.

By D. Osei-Hyiaman, M. Depetrillo, P. Pacher, Jie Liu, S. Radaeva, S. Batkai, J. Harvey‐White, K. Mackie, László Offertáler, Lei Wang and 1 more. Journal of Clinical Investigation, 2005

1,097 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Pharmacology, Physiology

View Paper: https://www.semanticscholar.org/paper/37c952d7e1ba7d2bd0be71351c2372aaf8c79600

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. N. Delzenne
2. Patrice D Cani

In Pharmacology

1. G. Marsicano
2. P. Pacher
3. P. Greasley
4. S. Batkai
5. George Kunos
6. B. Lutz

In Physiology

1. Patrice D Cani
2. N. Delzenne
3. F. Bäckhed
4. P. Pacher
5. Rob Knight
6. W. D. de Vos

Citations in the corpus

• The emerging role of the endocannabinoid system in endocrine regulation and energy balance. (2006, background): “In such a scenario, it has recently been proposed that via CB1 receptors, endocannabinoids may modulate the fatty acid synthetic pathway in the hypothalamus, and the inhibition of the hypothalamic expression by rimonabant may explain the anorexigenic properties of cannabinoid antagonists (62).”
• The metabolic syndrome. (2003, neutral): “Activation of central cannabinoid receptors stimulates eating and may contribute to obesity [60].”
• Activation of the peripheral endocannabinoid system in human obesity. (2005, background): “In contrast, CB-1 receptor density increases in the liver of mice fed a high-fat diet (18), and CB-1 receptor gene expression is increased in adipose tissue of obese Zucker rats (fa/fa) but unchanged in the uterus of ob/ob mice (17,25).”
• The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “…to increase SREBP1c and FAS gene expression in the hypothalamus, and the increased expression of these genes by fasting/refeeding (Paulaskis and Sul, 1988) could be inhibited by SR141716 treatment at the beginning of the refeeding period, which also reduced food intake (Osei-Hyiaman et al., 2005b).”
• Palmitic Acid: Physiological Role, Metabolism and Nutritional Implications (2017, background): “Noteworthy, it has been shown that treatment with endocannabinoid receptor agonist increased DNL in the mouse liver or in isolated hepatocytes (Osei-Hyiaman et al., 2005).”
• The endocannabinoid system links gut microbiota to adipogenesis (2010, background): “Indeed, we found that activation of the cannabinoid receptors markedly increased the expression of genes involved in adipocyte differentiation (PPAR-g, aP2, C/EBP-a) (Figure 7B) and lipogenesis (SREBP-1c, ACC, FAS), without affecting CB1 mRNA levels (Figure 7C).”
• The orphan receptor GPR55 is a novel cannabinoid receptor (2007, background): “Recently, the liver and adipose has been added to the list (Cota et al., 2003; Osei-Hyiaman et al., 2005).”